"One really needs to assess growth dynamics against previous corresponding periods.
In that case, you'll find that Zameen's Revenue fell by just 4% on pcp.
And that's in A$ terms, remember.
With the Australian Dollar to Pakistan Rupee exchange rate having fallen to around 145 in DQ22, from around 125 in DQ21 (so around 15%), it meant that Zameen grew by more than 10% in constant currency terms (which is, after all, the thing that matters when it comes to assessing real underlying business performance)."
...
Not sure how you calculate a "grew by more than 10% in constant currency terms" I calculate a 28% drop in Revenue offset by the 15% fall in the exchange rate, or a 13% drop overall.
On a pcp basis, 4Q is only a 4% drop from 4Q 2021 but this comes after the pcp outperformance of 1Q (60%) 2Q (63%) 3Q (38%).
So it is hard to argue the Zameen growth story hasn't taken a hit, and needs to recover in 2023.
Given the continued drop in Pakistan rupee (see previous post), it is unlikely we will see any recovery in AUD terms in 1Q 2023.
- Forums
- ASX - By Stock
- FDV
- Ann: Quarterly Activity Report and Appendix 4C
Ann: Quarterly Activity Report and Appendix 4C, page-24
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FDV (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
-0.010(2.56%) |
Mkt cap ! $164.7M |
Open | High | Low | Value | Volume |
38.5¢ | 39.0¢ | 38.0¢ | $110.9K | 286.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 73259 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 37175 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 73259 | 0.380 |
1 | 10000 | 0.375 |
3 | 106000 | 0.370 |
8 | 88426 | 0.365 |
5 | 210906 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 37175 | 1 |
0.395 | 14999 | 1 |
0.400 | 850 | 1 |
0.405 | 63713 | 1 |
0.410 | 42243 | 3 |
Last trade - 15.59pm 10/10/2024 (20 minute delay) ? |
Featured News
FDV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online